Please use this identifier to cite or link to this item:
|Title:||Metabotropic glutamate receptors as targets for novel antipsychotic treatments||Authors:||Gray, L.J.
Metabotropic glutamate receptors
|Issue Date:||Jun-2012||Abstract:||In recent years metabotropic glutamate receptors have emerged as key targets for the design of new antipsychotic medications for schizophrenia, in particular mGluR5 and mGluR2/3. These receptors exhibit diverse interactions with other neurotransmitter receptors and critical elements of intracellular signalling cascades known to be important to the pharmacotherapy of schizophrenia. In addition, mGluR5 and mGluR2/3 are intimately involved in behavioural domains related to the symptoms of this disorder. Both animal and clinical studies using novel drugs targeting these receptors have provided encouraging results. The number of patents registered for drugs targeting metabotropic glutamate receptors has grown dramatically, and positive allosteric modulators for both receptors show particular promise. © 2012 Bentham Science Publishers.||Source Title:||Current Pharmaceutical Biotechnology||URI:||http://scholarbank.nus.edu.sg/handle/10635/126517||ISSN:||13892010||DOI:||10.2174/138920112800784817|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.